BAYER AG NA O.N.
Commented by Stefan Feulner on July 17th, 2024 | 06:30 CEST
BioNTech, Cardiol Therapeutics, Bayer - Prepared for the next wave
The assassination attempt on former and possibly future US President Donald Trump was clearly the dominant topic at the weekend, causing both gold and the largest cryptocurrencies to surge at the start of the week. Still largely unnoticed, however, the COVID-19 figures are rising again, especially in the United States, which could halt the downward spiral for vaccine manufacturers such as BioNTech/Pfizer and Moderna.
Read
Commented by André Will-Laudien on July 1st, 2024 | 07:00 CEST
Attention: Biotech stocks! Evotec, Bayer, and BioNTech in the emergency room, but Cardiol Therapeutics shows strength!
Anyone looking at the buying frenzy on the NASDAQ is overlooking the fact that the US has long been in the emergency room. With the candidates currently up for election, it is unlikely that the most pressing issues of the day will be dealt with. One has difficulty using the right words in front of the camera, while the other ignores facts and slips into his own world. This election could be disastrous for the world's largest economy, but the financial markets are currently uninterested. Investors should, therefore, continue to separate the wheat from the chaff and act prudently. After the big AI and high-tech wave, biotechs are expected to make a comeback, as US interest rates will drop closer to the election. We present a solid selection for risk-conscious investors.
Read
Commented by Fabian Lorenz on June 25th, 2024 | 07:00 CEST
300%-Opportunity, problems, and the German Chancellor: Bayer, BioNTech, and Cardiol Therapeutics
Bayer is making positive headlines for a change. Following takeovers in cell and gene therapy, the Company is investing in Berlin and has brought the renowned Charité Hospital on board. Federal Chancellor Olaf Scholz gives the go-ahead for the project. Can the share benefit from this? The sell-off in Cardiol Therapeutics shares after positive study results was a surprise. Analysts are enthusiastic, raising price targets and seeing 300% potential. On the other hand, BioNTech shares are currently not an obvious buy. And now there are also problems with the FDA in the US. This is causing alarm among shareholders and impacting the share.
Read
Commented by André Will-Laudien on June 21st, 2024 | 07:00 CEST
Biotech: What counts is selection! Bayer, Vidac Pharma, Formycon, and Evotec in focus
The biotech sector has so far been unable to keep pace with the high-tech-heavy NASDAQ. However, there are now signals from the central banks that a turnaround in interest rates is imminent. This is because, on the one hand, the US economy is weakening, and on the other hand, inflationary pressure appears to be easing. With lower interest rates, life science companies can refinance themselves more cheaply. Due to the different dynamics, it is now important to fish out the pearls. We select attractive entry levels.
Read
Commented by Fabian Lorenz on June 18th, 2024 | 06:30 CEST
Price jump at TUI! Bayer share price slumps! Globex Mining makes millions!
TUI shares were among the day's winners on the German stock market yesterday. The tourism group benefited not only from positive analyst comments but also from the FTI bankruptcy. Can the share now end its months-long sideways movement? There are also good reasons for higher prices at Globex Mining. The mining incubator recently received CAD 3 million from the gold group Agnico Eagle - and that is not the end of the story. The latest analyst comments on Bayer shares are not very promising. Yesterday's DAX share price reaction was correspondingly negative. However, the management was optimistic.
Read
Commented by Armin Schulz on June 10th, 2024 | 07:15 CEST
Evotec, Vidac Pharma, Bayer - Biotech and Pharma: Opportunities for investors
In the constantly evolving pharmaceutical and biotechnology industry landscape, innovative strength and strategic orientation play a decisive role in success. Both established groups and young, up-and-coming companies are competing for market share and scientific breakthroughs. In this context, it is worth taking a closer look at Vidac Pharma, Bayer and Evotec. These companies are pursuing different approaches and strategies to achieve their respective goals. How do they manage to hold their own in a highly dynamic market environment, and what prospects are emerging for the future?
Read
Commented by André Will-Laudien on June 6th, 2024 | 07:00 CEST
Rally start for biotech! Evotec, Bayer, Defence Therapeutics, CureVac and BioNTech in pole position
Sell in May and go Away! Far from it, as the stock markets continue to rise steadily in June. After a disappointing start to the year, the biotech sector is now also showing signs of recovery. Bayer and Evotec seem to have found their footing with improved outlooks. BioNTech, CureVac and Defence Therapeutics are providing promising data on various cancer vaccines. Whoever opens the door here can save millions of lives. And investors stand to make a fortune if one of the vaccines hits the mark. We analyze the opportunities and risks.
Read
Commented by Armin Schulz on June 5th, 2024 | 07:00 CEST
Bayer, Saturn Oil + Gas, TUI - Big price gains beckon here
The shares of Bayer, Saturn Oil & Gas and TUI have the potential to rise in the near future. At Bayer, the negative effects of the challenging year 2023 appear to have been priced in. Saturn Oil & Gas impresses with a strong cash flow and is traded as a future dividend share. Analysts see potential of over 100% here. TUI's balance sheet problems have largely been resolved, and the forecasts for 2024 and the summer season promise record bookings, which could give the share an additional boost - reason enough for us to take a closer look at the three companies.
Read
Commented by André Will-Laudien on May 30th, 2024 | 07:00 CEST
Already up 180% in 2024 - Who offers more? BioNTech, Bayer, Cardiol Therapeutics, or Evotec?
For investors in the biotech sector, 2024 has been a very rocky year. Everyone is waiting for the big breakthrough, which has yet to appear. In a sector where there is no longer a pandemic and cancer research is still stuck, selection has become very important. Complicating matters is the investor-unfriendly capital market interest rate, with hopes resting on support from central banks quarter by quarter. This makes it all the more important to identify and follow the most innovative business models. BioNTech does not currently have a blockbuster but still has a good EUR 17 billion in its coffers. Pharmaceutical giant Bayer has seen its share price drop to a fifth of its 2019 value, and Evotec also resembles a disaster. Cardiol Therapeutics has performed well so far - what is next for them?
Read
Commented by Juliane Zielonka on May 24th, 2024 | 07:00 CEST
NVIDIA, Vidac Pharma, Bayer - Opportunities for innovation and growth
The next industrial revolution has begun – companies and countries are working with firms like NVIDIA to transform traditional data centres worth billions of euros into accelerated computing hubs and build a new type of data centre: AI factories to produce artificial intelligence. The areas of application are vast, including data processing, generative AI, pharmaceutical research, weather simulations, robotics and many more. Vidac Pharma, for example, is an exciting candidate in the field of drug research. Their innovative approach in oncology can reverse the function of cancer cells. If successful, Bayer would have less to worry about. The Leverkusen-based company is fighting the wave of US lawsuits in connection with RoundUp®. The glyphosate-based herbicide is suspected of causing cancer. Bayer is now pursuing a new strategy in the face of the six-figure lawsuits. Where do investors find the best innovations and greatest growth opportunities?
Read